Antibiotic susceptibility of Helicobacter pylori in central Germany and its relationship with the number of eradication therapies

European Journal of Gastroenterology and Hepatology

Volumn 25, Issue 11, 2013, Pages 1257-1260

  Selgrad, Michael ^a   Meile, Julia ^a   Bornschein, Jan ^a   Kandulski, Arne ^a   Langner, Cosima ^a   Varbanova, Mariya ^a   Wex, Thomas ^a,b   Tammer, Ina ^a   Schlüter, Dirk ^a   Malfertheiner, Peter ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b Medical Laboratory for Clinical Chemistry Microbiology and Infectious Diseases Department of Molecular Genetics   (Germany)

Author keywords

antibiotic resistance; antibiotic susceptibility; Helicobacter pylori treatment

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; LEVOFLOXACIN; METRONIDAZOLE; RIFABUTIN; TETRACYCLINE;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; ATROPHIC GASTRITIS; BACTERIAL STRAIN; CHRONIC GASTRITIS; DUODENUM ULCER; EPSILOMETER TEST; ERADICATION THERAPY; FEMALE; GASTROSCOPY; GERMANY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STOMACH CANCER; STOMACH ULCER; ULCER;

ADULT; AGED; ANTI-BACTERIAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; FEMALE; GASTROSCOPY; GERMANY; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84885327762     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3283643491     Document Type: Article

References (19)

1. Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, et al. Management of Helicobacter pylori infection - the Maastricht IV/ Florence Consensus Report. Gut 2012; 61:646-664.
2. Wex T, Venerito M, Kreutzer J, Gotze T, Kandulski A, Malfertheiner P. Serological prevalence of Helicobacter pylori infection in Saxony-Anhalt, Germany, in 2010. Clin Vaccine Immunol 2011; 18:2109-2112.
3. Malfertheiner P, Selgrad M, Bornschein J. Helicobacter pylori: clinical management. Curr Opin Gastroenterol 2012; 28:608-614.
4. Selgrad M, Malfertheiner P. Treatment of Helicobacter pylori. Curr Opin Gastroenterol 2011; 27:565-570.
5. Fischbach W, Malfertheiner P, Hoffmann JC, Bolten W, Bornschein J, Gotze O, et al. S3-guideline "Helicobacter pylori and gastroduodenal ulcer disease" of the German society for digestive and metabolic diseases (DGVS) in cooperation with the German society for hygiene and microbiology, society for pediatric gastroenterology and nutrition e. V., German society for rheumatology, AWMF-registration-no. 021/001. Z Gastroenterol 2009; 47:1230-1263.
6. Fock KM, Katelaris P, Sugano K, Ang TL, Hunt R, Talley NJ, et al. Second Asia-Pacific consensus guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol 2009; 24:1587-1600.
7. Megraud F, Lehours P. Helicobacter pylori detection and antimicrobial susceptibility testing. Clin Microbiol Rev 2007; 20:280-322.
8. Wueppenhorst N, Stueger HP, Kist M, Glocker E. Identification and molecular characterization of triple- and quadruple-resistant Helicobacter pylori clinical isolates in Germany. J Antimicrob Chemother 2009; 63: 648-653.
9. Cederbrant G, Kahlmeter G, Ljungh A. The E test for antimicrobial susceptibility testing of Helicobacter pylori. J Antimicrob Chemother 1993; 31:65-71.
10. Glupczynski Y, Labbe M, Hansen W, Crokaert F, Yourassowsky E. Evaluation of the E test for quantitative antimicrobial susceptibility testing of Helicobacter pylori. J Clin Microbiol 1991; 29:2072-2075.
11. Wolle K, Leodolter A, Malfertheiner P, Konig W. Antibiotic susceptibility of Helicobacter pylori in Germany: stable primary resistance from 1995 to 2000. J Med Microbiol 2002; 51:705-709.
12. Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther 2007; 26:343-357.
13. Megraud F. H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004; 53:1374-1384.
14. Malfertheiner P, Bazzoli F, Delchier JC, Celinski K, Giguere M, Riviere M, et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, noninferiority, phase 3 trial. Lancet 2011; 377:905-913.
15. Glocker E, Stueger HP, Kist M. Quinolone resistance in Helicobacter pylori isolates in Germany. Antimicrob Agents Chemother 2007; 51:346-349.
16. Oleastro M, Cabral J, Ramalho PM, Lemos PS, Paixao E, Benoliel J, et al. Primary antibiotic resistance of Helicobacter pylori strains isolated from Portuguese children: a prospective multicentre study over a 10 year period. J Antimicrob Chemother 2011; 66:2308-2311.
17. Megraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl AM, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2012; 62:34-42.
18. Karczewska E, Wojtas-Bonior I, Sito E, Zwolinska-Wcislo M, Budak A. Primary and secondary clarithromycin, metronidazole, amoxicillin and levofloxacin resistance to Helicobacter pylori in southern Poland. Pharmacol Rep 2011; 63:799-807.
19. Raymond J, Lamarque D, Kalach N, Chaussade S, Burucoa C. High level of antimicrobial resistance in French Helicobacter pylori isolates. Helicobacter 2010; 15:21-27.